0334 GMT - Telix Pharmaceuticals' US$2.35 billion acquisition of ITM gives the Australian company unparalleled exposure to the supply chain for cancer treatments' dominant therapeutic isotope, Bell Potter analyst John Hester says. Hester highlights to clients in a note ITM's position as a leading manufacturer of isotopes including 177Lu, which he points out is used in treatments including Novartis's Pluvicto. With margins on ITM's isotope production well in advance of TLX's margins on its manufacturing, his initial view is that the acquisition makes a lot of strategic sense. Bell Potter is reviewing its forecasts for Telix and its target price on the stock. Shares are down 5.1% at 16.94 Australian dollars.